Skip to main content
EnglishEN
European Commission logo print header

The European medical isotope programme: Production of high purity isotopes by mass separation

Project description

DEENESFRITPL

European infrastructure for radionuclide production

Nuclear medicine uses radioactive molecules, so-called radiopharmaceuticals, and their radiation to provide diagnostic information and treat various medical conditions such as cancer. The radioactive elements, known as radionuclides, possess excess energy that is released by different types of radioactive decay. The key objective of the EU-funded PRISMAP project is to establish a European infrastructure and a common entry point for researchers and physicians in the field. The consortium will set up a sustainable source of highly pure non-conventional radionuclides for developments in medicine as well as protocols and services for the pharmaceutical industry and the healthcare sector, in a sustainable European medical radionuclide programme.

Objective

PRISMAP - The European medical isotope programme: Production of high purity isotopes by mass separation proposes to federate a consortium of the key European intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical research institutes and hospitals active in the translation of the emerging radionuclides into medical diagnosis and treatment. PRISMAP will create a single-entry point for a fragmented user community distributed amongst universities, research centres, industry and hospitals, in a similar way as the National Isotope Development Center NIDC supported by the Department of Energy (DOE) has provided radionuclide sources for users in the USA. PRISMAP brings together a consortium of 23 beneficiaries from 13 countries, one European Research Laboratory and an International Organisation. It further receives support of leading associations and institutions in the field such as the European Association of Nuclear Medicine (EANM) and the International Atomic Energy Agency (IAEA). Our main goal is to provide a sustainable source of high purity grade new radionuclides for medicine, involving from the onset upcoming major European infrastructures, to provide a single-entry point for all researchers active in this field including SMEs, global pharma, nuclear centres, hospitals and universities, using standardised access procedures. The new isotope enrichment and standardisation techniques triggered in PRISMAP will expand our services and provide them to yet unreachable remote European laboratories. PRISMAP thus strives to create a paradigm shift in the early phase research on radiopharmaceuticals, targeted drugs for cancer – one of the major diseases in Europe - theranostics and personalised medicine, shaping the European isotope landmark as a gold standard to accelerate the development of the pharma industry and ultimately of a better healthcare for the improvement of our citizens’ life.

Fields of science

Programme(s)

Topic(s)

Call for proposal

H2020-INFRAIA-2018-2020

See other projects for this call

Sub call

H2020-INFRAIA-2020-1

Funding Scheme

RIA - Research and Innovation action

Coordinator

ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE
Net EU contribution
€ 1 032 220,00
Address
Esplanade des particules 1 parcelle 11482 de meyrin batiment cadastral 1046
1211 Geneve 23
Switzerland

See on map
Region
Schweiz/Suisse/Svizzera Région lémanique Genève
Activity type
Research Organisations
Links
Other funding
€ 0,00

Participants (22)

Share this page

Download

EC signature date 7 July 2021
Last update: 10 March 2023

My Booklet

Permalink: https://cordis.europa.eu/project/id/101008571

European Union, 2023